~~<i id='7F2C962604'><strike id='7F2C962604'><tt id='7F2C962604'><pre id='7F2C962604'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：comprehensive 2025-09-27 21:18:57 Page View：569

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： SNAP should offer more nutrition education
Next article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

knowledge

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

Eli Lilly reports tirzepatide MASH success during Q4 earnings

DarronCummings/APTheblockbusterweightlossanddiabetesdrugsoldbyEliLillyalsoappearstoimprovefattyliver

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

Prime Medicine, Myeloid Therapeutics clash over genome

AdobeThecloselywatchedgene-editingstartupPrimeMedicineisembroiledinamultimillion-dollardisputewithan